The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 16th Jan 2013 07:16

Anglo American: Goldman Sachs reduces target price from 1650p to 1500p and reiterates its sell recommendation.Antofagasta: Goldman Sachs ups target price from 1100p to 1120p and still recommends to sell.ARM Holdings: UBS increases target price from 750p to 900p, while downgrading to neutral.Ashtead Group: Credit Suisse raises target price from 400p to 545p retaining an outperform rating.Balfour Beatty: Credit Suisse shifts target price from 275p to 279p and keeps a neutral rating.Barclays: Nomura ups target price from 230p to 270p maintaining a reduce rating.Barratt Developments: Panmure Gordon shifts target price from 211p to 220p and retains a hold recommendation.Berendsen: Credit Suisse increases target price from 640p to 710p and maintains an outperform rating.BHP Billiton: JP Morgan takes target price from 2245p to 2300p and keeps a neutral rating. Goldman Sachs ups target price from 2400p to 2450p, while its buy recommendation remains unchanged.Brammer: Jefferies raises target price from 295p to 340p and downgrades from buy to hold.BT Group: Deutsche Bank increases target price from 235p to 269p, while retaining a hold rating.Burberry Group: UBS moves target price from 1170p to 1350p and reiterates a neutral rating. Credit Suisse ups target price from 1430p to 1550p, while staying with its outperform rating. Berenberg takes price target from 1400p to 1600p keeping a buy recommendation.Capital Shopping Centres Group: JP Morgan increases target price from 380p to 400p and upgrades to neutral.Carillion: Credit Suisse ups target price from 316p to 349p and downgrades to neutral.Centrica: Barclays raises target price from 305p to 325p and keeps an underweight rating.Charlemagne Capital: JP Morgan shifts target price from 5p to 7p, while retaining an underweight rating.COLT Telecom Group: Deutsche Bank cuts target price from 155p to 145p, while its buy recommendation is reiterated.Communisis: Panmure Gordon downgrades from buy to hold with its target price still at 47p.Diageo: Nomura lowers target price from 2070p to 2040p, while the buy rating is kept. Societe Generale reduces target price from 2050p to 1900p and downgrades to hold.Eurasian Natural Resources Corporation: JP Morgan ups target price from 275p to 300p, while the neutral rating is maintained.Fenner: Investec shifts target price from 415p to 420p, while retaining a hold rating.French Connection: Seymour Pierce cuts target price from 25p to 20p still recommending to hold.Glaxo Smith Kline: Jefferies raises target price from 1450p to 1500p and reiterates a hold rating.Home Retail Group: Barclays shifts target price from 70p to 73p and retains an underweight rating.HSBC Holdings: Nomura increases target price from 660p to 730p staying with its buy recommendation.Intermediate Capital Group: Deutsche Bank ups target price from 298p to 322p and keeps a hold rating.ITV: JP Morgan moves target price from 109p to 120p and downgrades to neutral.Kazakhmys: Goldman Sachs cuts target price from 850p to 820p, while its neutral rating is reiterated.Liontrust Asset Management: JP Morgan ups target price from 112p to 134p, while keeping an underweight rating.Lonmin: After Lonmin has not been rated, Investec recommends to hold with its target price at 353p.Lloyds Banking Group: Nomura shifts target price from 37p to 42p and maintains a reduce rating.MITIE Group: Credit Suisse reduces target price from 290p to 250p and keeps an underperform rating.N Brown: Seymour Pierce moves target price from 280p to 360p reiterating its hold recommendation.Provident Financial: JP Morgan ups target price from 1626p to 1646p, while maintaining an overweight rating.Rio Tinto: UBS reduces target price from 4340p to 4320p keeping its buy recommendation. JP Morgan raises target price from 4200p to 4400p and reiterates an overweight rating. Goldman Sachs increases target price from 3400p to 3800p, while its neutral rating remains unchanged. Deutsche Bank lowers target price from 4520p to 4450p and maintains a buy recommendation. Morgan Stanley downgrades to equalweight. Rolls-Royce Group: Credit Suisse takes price target from 850p to 900p and retains a neutral rating.Royal Bank of Scotland: Nomura raises target price from 270p to 300p and stays with a reduce rating.RPS Group: Investec moves target price from 270p to 275p keeping a buy recommendation.SAB Miller: Nomura shifts target price from 2800p to 2840p maintaining a neutral rating.Signet Jewelers: UBS ups target price from 3700p to 4050p, while its buy recommendation remains unchanged.Standart Chartered: Nomura moves target price from 1600p to 1800p reiterating a buy rating.Tarsus Group: Investec takes price target from 210p to 215p, while its buy rating in unchanged.Thorntons: Investec increases target price from 30p to 45p and stays with a hold recommendation.Virgin Media: Deutsche Bank raises target price from 2325p to 3154p, while its buy recommendation is maintained.Vodafone: Deutsche Bank cuts target price from 225p to 175p and downgrades to hold.Wetherspoon JD: Investec lowers target price from 570p to 550p and retains its buy recommendation.
More News
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
21 Nov 2023 11:52

GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024

(Alliance News) - GSK PLC on Tuesday said it will begin phase 3 trials of a low carbon version of its metered dose inhaler Ventolin using a "next generation" propellant in 2024.

Read more
14 Nov 2023 17:04

LONDON MARKET CLOSE: FTSE 100 underwhelms as stocks jump after US CPI

(Alliance News) - European equities jumped in the wake of a cooler-than-expected US inflation reading, which took some sting out of a recent hawkish reassessment of the Federal Reserve interest rate outlook.

Read more
13 Nov 2023 09:47

GSK hails momelotinib opinion from European Medicines Agency committee

(Alliance News) - GSK PLC on Monday announced that a European Medicines Agency panel has given a positive opinion recommending momelotinib to treat myelofibrosis patients with anaemia.

Read more
9 Nov 2023 15:50

UK dividends calendar - next 7 days

Friday 10 November 
Bodycote PLCdividend payment date
Breedon Group PLCdividend payment date
Chesnara PLCdividend payment date
Finsbury Growth & Income Trust PLCdividend payment date
Invesco Bond Income Plus Ltddividend payment date
JPMorgan Emerging Markets Investment Trust PLCdividend payment date
Kerry Group PLCdividend payment date
Merchants Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCspecial dividend payment date
Montanaro UK Smaller Cos Investment Trust PLCdividend payment date
Senior PLCdividend payment date
Spectris PLCdividend payment date
Spirax-Sarco Engineering PLCdividend payment date
Travis Perkins PLCdividend payment date
Monday 13 November 
no events scheduled 
Tuesday 14 November 
no events scheduled 
Wednesday 15 November 
Coats Group PLCdividend payment date
Ferguson PLCdividend payment date
JP Morgan Mid Cap Investment Trust PLCdividend payment date
Strategic Equity Capital PLCdividend payment date
Thursday 16 November 
abrdn Property Income Trust Ltdex-dividend payment date
Asian Energy Impact Trust PLCex-dividend payment date
Baillie Gifford Japan Trust PLCex-dividend payment date
BlackRock Greater Europe Investment Trust PLCex-dividend payment date
Bunzl PLCex-dividend payment date
Bytes Technology Group PLCex-dividend payment date
Centrica PLCdividend payment date
Coca-Cola Europacific Partners PLCex-dividend payment date
DX Group PLCex-dividend payment date
Empiric Student Property PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
GCP Asset Backed Income Fund Ltdex-dividend payment date
GSK PLCex-dividend payment date
Hargreaves Lansdown PLCex-dividend payment date
Henderson Opportunities Trust PLCex-dividend payment date
ICG Enterprise Trust PLCex-dividend payment date
James Halstead PLCex-dividend payment date
Lancashire Holdings Ltdspecial ex-dividend payment date
Majedie Investments PLCex-dividend payment date
Marks & Spencer Group PLCex-dividend payment date
Murray Income Trust PLCex-dividend payment date
New Star Investment Trust PLCex-dividend payment date
NextEnergy Solar Fund Ltdex-dividend payment date
Octopus Renewables Infrastructure Trust PLCex-dividend payment date
Pershing Square Holdings Ltdex-dividend payment date
Personal Group Holdings PLCdividend payment date
Redrow PLCdividend payment date
Regional REIT Ltdex-dividend payment date
Schroder Oriental Income Fund Ltdex-dividend payment date
Scottish American Investment Co PLCex-dividend payment date
SCS Group PLCex-dividend payment date
Shell PLCex-dividend payment date
Supermarket Income REIT PLCdividend payment date
UK Commercial Property REIT Ltdex-dividend payment date
Unilever PLCex-dividend payment date
Wincanton PLCex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
8 Nov 2023 09:30

LONDON BROKER RATINGS: UBS downbeat on AJ Bell and Hargreaves Lansdown

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
2 Nov 2023 10:14

LONDON BROKER RATINGS: Bank of America starts Unite Group with 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.